Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: A review

Neuropsychiatric Disease and Treatment

Volumn 5, Issue 1, 2009, Pages 215-226

  Hammerness, Paul ^a   McCarthy, Katherine ^a   Mancuso, Elizabeth ^a   Gendron, Cassandra ^a   Geller, Daniel ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

ADHD; Atomoxetine; Pediatric

Indexed keywords

ALANINE AMINOTRANSFERASE; AMPHETAMINE; ANTIDEPRESSANT AGENT; ASPARTATE AMINOTRANSFERASE; ATOMOXETINE; BENZODIAZEPINE DERIVATIVE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CENTRAL STIMULANT AGENT; CITALOPRAM; DOPAMINE; FLUOXETINE; FLUVOXAMINE; METHYLPHENIDATE; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NORADRENALIN; PAROXETINE; PLACEBO; QUINIDINE; SALBUTAMOL; SEROTONIN; VENLAFAXINE;

ADOLESCENT; AGGRESSION; AGITATION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANXIETY DISORDER; APPETITE; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATTENTION DEFICIT DISORDER; AUTISM; CHILD; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG OVERDOSE; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FATIGUE; GASTROINTESTINAL SYMPTOM; HEART RATE; HUMAN; INSOMNIA; IRRITABILITY; LIVER INJURY; LIVER TOXICITY; MAINTENANCE THERAPY; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MOOD DISORDER; NEUROTOXICITY; NONHUMAN; NOTE; OPPOSITIONAL DEFIANT DISORDER; PSYCHOSIS; RELAPSE; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP DISORDER; SOMNOLENCE; SUDDEN DEATH; SUICIDAL BEHAVIOR; TIC; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; UPPER ABDOMINAL PAIN; VITAL SIGN; VOMITING;

EID: 70449718852     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: None     Document Type: Note

References (68)

1. Visser SN, Lesesne CA, Perou R. National estimates and factors associated with medication treatment for childhood attention-deficit/hyperactivity disorder. Pediatrics. 2007;119 Suppl 1:S99-S106. (Pubitemid 46397953)
2. Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894-921.
3. Brown RT, Amler RW, Freeman WS, et al. Treatment of attention-deficit/ hyperactivity disorder: overview of the evidence. Pediatrics. 2005;115(6):e749-e757. (Pubitemid 43843150)
4. Wong DT, Threlkeld PG, Best KL, Bymaster FP. A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain. J Pharmacol Exp Ther. 1982;222(1):61-65.
5. Bolden-Watson C, Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci. 1993;52(12):1023-1029. (Pubitemid 23057151)
6. Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002;27(5):699-711.
7. Swanson CJ, Perry KW, Koch-Krueger S, Katner J, Svensson KA, Bymaster FP. Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat. Neuropharmacology. 2006;50(6):755-760.
8. Witcher JW, Long A, Smith B, et al. Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 2003;13(1):53-63. (Pubitemid 36570188)
9. Sauer JM, Ring BJ, Witcher JW. Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet. 2005;44(6):571-590.
10. Corman SL, Fedutes BA, Culley CM. Atomoxetine: the first non-stimulant for the management of attention-deficit/hyperactivity disorder. Am J Health Syst Pharm. 2004;61(22):2391-2399. (Pubitemid 40403582)
11. Ring BJ, Gillespie JS, Eckstein JA, Wrighton SA. Identification of the human cytochromes P450 responsible for atomoxetine metabolism. Drug Metab Dispos. 2002;30(3):319-323. (Pubitemid 34175024)
12. Sauer JM, Ponsler GD, Mattiuz EL, et al. Disposition and metabolic fate of atomoxetine hydrochloride: The role of CYP2D6 in human disposition and metabolism. Drug Metab Dispos. 2003;31:98-107. (Pubitemid 36735263)
13. Michelson D, Adler L, Amsterdam J, et al. Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(4):582-587. (Pubitemid 46663041)
14. Chalon SA, Desager JP, Desante KA, et al. Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites. Clin Pharmacol Ther. 2003;73(3):178-191. (Pubitemid 36269669)
15. Spencer T, Biederman J, Heiligenstein J, et al. An Open-Label, Dose-Ranging Study of Atomoxetine in Children with Attention Deficit Hyperactivity Disorder. J Child Adolesc Psychopharmacol. 2001;11(3):251-265. (Pubitemid 32937637)
16. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose-response study. Pediatrics. 2001;108(5).
17. Weiss M, Tannock R, Kratochvil C, et al. A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2005;44(7):647-655. (Pubitemid 40875359)
18. Cheng JY, Chen RY, Ko JS, Ng EM. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta- analysis and meta-regression analysis. Psychopharmacology (Berl). 2007;194(2):197-209.
19. Kratochvil CJ, Milton DR, Vaughan BS, Greenhill LL. Acute atomoxetine treatment of younger and older children with ADHD: A meta-analysis of tolerability and efficacy. Child Adolesc Psychiatry Ment Health. 2008;2(1):25.
20. Faraone SV, Biederman J, Spencer TJ, Aleardi M. Comparing the efficacy of medications for ADHD using meta-analysis. Med Gen Med. 2006;8(4):4. (Pubitemid 44541837)
21. Kemner JE, Starr HL, Ciccone PE, Hooper-Wood CG, Crockett RS. Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study. Adv Ther. 2005;22(5):498-512. (Pubitemid 43130867)
22. Wigal SB, McGough JJ, McCracken JT, et al. A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. J Atten Disord. 2005;9(1):275-289.
23. Kratochvil CJ, Heiligenstein JH, Dittman R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: A prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry. 2002;41(7):776-784. (Pubitemid 38338092)
24. Wilens TE, Newcorn JH, Kratochvil CJ, et al. Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder. J Pediatr. 2006;149(1):112-119. (Pubitemid 44081915)
25. Michelson D, Allen AJ, Busner J, et al. Once-Daily Atomoxetine Treatment for Children and Adolescents with Attention Deficit Hyperactivity Disorder: A Randomized, Placebo-Controlled Study. Am J Psychiatry. 2002;159(11):1896-1901. (Pubitemid 35283256)
26. Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics. 2004;114(1):e1-e8.
27. Newcorn JH, Kratochvil CJ, Allen AJ, et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry. 2008;165(6):721-730.
28. Quintana H, Cherlin EA, Duesenberg DA, et al. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder - a preliminary tolerability and efficacy study. Clin Ther. 2007;29(6):1168-1177. (Pubitemid 47198889)
29. Hammerness P, Mick E, Doyle R, et al. Atomoxetine in children with attention deficit hyperactivity disorder (ADHD) with prior poor response to stimulant therapy: a prospective open label study. Eur Child Adolesc Psychiatry. 2009; in revision.
30. Kratochvil CJ, Michelson D, Newcorn JH, et al. High-dose atomoxetine treatment of ADHD in youths with limited response to standard doses. J Am Acad Child Adolesc Psychiatry. 2007;46(9):1128-1137. (Pubitemid 47295924)
31. Safer DJ, Zito JM, DosReis S. Concomitant psychotropic medication for youths. Am J Psychiatry. 2003;160(3):438-449.
32. Carlson GA, Dunn D, Kelsey D, et al. A pilot study for augmenting atomoxetine with methylphenidate: safety of concomitant therapy in children with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatry Ment Health. 2007;1(1):10.
33. Wilens T, Hammerness P, Utzinger L, et al. An open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: I. effectiveness. J Child Adolesc Psychopharmacol. In press.
34. Kratochvil C, Wilens T, Greenhill L, et al. Effects of long-term atomoxetine treatment for young children with Attention-deficit/hyperactive disorder. J Am Acad Child Adolesc Psychiatry. 2006;45(8):919-927. (Pubitemid 44126866)
35. Spencer TJ, Kratochvil CJ, Sangal RB, et al. Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment. J Child Adolesc Psychopharmacol. 2007;17(5):689-699.
36. Bakken RJ, Paczkowski M, Kramer HP, et al. Effects of atomoxetine on attention-deficit/hyperactivity disorder in clinical pediatric treatment settings: a naturalistic study. Curr Med Res Opin. 2008;24(2):449-460. (Pubitemid 351294394)
37. Michelson D, Buitelaar JK, Danckaerts M, et al. Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry. 2004;43(7):896-904. (Pubitemid 38808495)
38. Michelson D. Treatment of ADHD: beyond stimulants. Presented at the 15th European Neuropsychopharmacology Congress, Barcelona, Spain. Eur Neuropsychopharmacol. 2002;12(Suppl 3):S77-S457.
39. Buitelaar JK, Michelson D, Danckaerts M, et al. A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year. Biol Psychiatry. 2007;61(5):694-699. (Pubitemid 46328852)
40. Biederman J, Spencer TJ, Newcorn JH, et al. Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data. Psychopharmacology (Berl). 2007;190(1):31-41. (Pubitemid 44885341)
41. Newcorn JH, Spencer TJ, Biederman J, Milton DR, Michelson D. Atomoxetine Treatment in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder. J Am Acad Child Adolesc Psychiatry. 2005;44(3):240-248. (Pubitemid 40299837)
42. Hazell P, Zhang S, Wolanczyk T, et al. Comorbid oppositional defiant disorder and the risk of relapse during 9 months of atomoxetine treatment for attention-deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry. 2006;15(2):105-110. (Pubitemid 43352184)
43. Spencer T, Heiligenstein JH, Biederman J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002;63(12):1140-1147. (Pubitemid 36084059)
44. Kaplan S, Heiligenstein J, West S, et al. Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder. J Atten Disord. 2004;8(2):45-52. (Pubitemid 40081859)
45. Bangs ME, Hazell P, Danckaerts M, et al. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder. Pediatrics. 2008;121(2):e314-e320. (Pubitemid 351198437)
46. Arnold P, Sicard T, Burroughs E, Richter M, Kennedy J. Glutamate transporter gene SLC1A1 associated with obsessive-oompulsive disorder. Arch Gen Psychiatry. 2006;63(7):717-720.
47. Troost PW, Steenhuis MP, Tuynman-Qua HG, et al. Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study. J Child Adolesc Psychopharmacol. 2006;16(5):611-619. (Pubitemid 44737214)
48. Posey D, Erickson C, Stigler KA, McDougle C. The use of selective serotonin reuptake inhibitors in autism and related disorders. J Child Adolesc Psychopharmacol. 2006;16(1-2):181-186.
49. Allen AJ, Kurlan R, Gilbert DL, et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology. 2005;65:1941-1949. (Pubitemid 43970115)
50. Geller D, Donnelly C, Lopez F, et al. Atomoxetine treatment for pediatric patients with ADHD and comorbid anxiety. J Am Acad Child Adolesc Psychiatry. 2007;46(9):11.
51. Abikoff H, McGough J, Vitiello B, et al. Sequential pharmacotherapy for children with comorbid Attention-Deficit/Hyperactivity and anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2005;44(5):418-427. (Pubitemid 40559689)
52. Bangs ME, Emslie GJ, Spencer TJ, et al. Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression. J Child Adolesc Psychopharmacol. 2007;17(4):407-420.
53. Kratochvil CJ, Newcorn JH, Arnold LE, et al. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry. 2005;44(9):915-924.
54. Hah M, Chang K. Atomoxetine for the treatment of attention-deficit/ hyperactivity disorder in children and adolescents with bipolar disorders. J Child Adolesc Psychopharmacol. 2005;15(6):996-1004. (Pubitemid 43042991)
55. Greenhill LL, Newcorn JH, Gao H, Feldman PD. Effect of two different methods of initiating atomoxetine on the adverse event profile of atomoxetine. J Am Acad Child Adolesc Psychiatry. 2007;46(5):566-572. (Pubitemid 46642573)
56. Polzer J, Bangs ME, Zhang S, et al. Meta-analysis of aggression or hostility events in randomized, controlled clinical trials of atomoxetine for ADHD. Biol Psychiatry. 2007;61(5):713-719. (Pubitemid 46328864)
57. Lim JR, Faught PR, Chalasani NP, Molleston JP. Severe liver injury after initiating therapy with atomoxetine in two children. J Pediatr. 2006;148(6):831-834.
58. Perrin JM, Friedman RA, Knilans TK. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics. 2008;122(2):451-453.
59. Association A. American Academy of Pediatrics/American Heart Association clarification of statement on cardiovascular evaluation and monitoring of children and adolscents with heart disease receiving medications for ADHD. May 16, 2008.
60. Wernicke JF, Holdridge KC, Jin L, et al. Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine. Dev Med Child Neurol. 2007;49(7):498-502. (Pubitemid 47018494)
61. Stojanovski SD, Robinson RF, Baker SD, Casavant MJ, Hayes JR, Nahata MC. Children and adolescent exposures to atomoxetine hydrochloride reported to a poison control center. Clin Toxicol (Phila). 2006;44(3):243-247. (Pubitemid 43982359)
62. Spiller HA, Lintner CP, Winter ML. Atomoxetine ingestions in children: a report from poison centers. Ann Pharmacother. 2005;39(6):1045-1048.
63. Lovecchio F, Kashani J. Isolated atomoxetine (Strattera) ingestions commonly result in toxicity. J Emerg Med. 2006;31(3):267-268. (Pubitemid 44374258)
64. Forrester MB. Adult atomoxetine ingestions reported to Texas Poison Control Centers, 2003-2005. Ann Pharmacother. 2006;40(12):2136-2141.
65. Kashani J, Ruha AM. Isolated atomoxetine overdose resulting in seizure. J Emerg Med. 2007;32(2):175-178. (Pubitemid 46329316)
66. Párraga H, Párraga M, Harris D. Tic exacerbation and precipitation during atomoxetine treatment in two children with attention-deficit hyperactivity disorder. Int J Psychiatry Med. 2007;37(4):415-424.
67. Bond GR, Garro AC, Gilbert DL. Dyskinesias associated with atomoxetine in combination with other psychoactive drugs. Clin Toxicol (Phila). 2007;45(2):182-185.
68. Allen AJ, Michelson D. Drug development process for a product with a primary pediatric indication. J Clin Psychiatry. 2002;(63 Suppl 12):44-49. (Pubitemid 36025587)